SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

ONC.US

254.35

-0.88%↓

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

ONC.US

254.35

-0.88%↓

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

ONC.US

254.35

-0.88%↓

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

ONC.US

254.35

-0.88%↓

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

ONC.US

254.35

-0.88%↓

Search

Fresenius SE & Co KGaA

Closed

SectorHealthcare

44.24 0.07

Overview

Share price change

24h

Current

Min

44.2

Max

44.39

Key metrics

By Trading Economics

Income

198M

471M

Sales

21M

5.7B

P/E

Sector Avg

23.257

51.198

Dividend yield

2.32

Profit margin

8.335

Employees

175,202

EBITDA

225M

949M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.75% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.32%

2.40%

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

3.4B

24B

Previous open

44.17

Previous close

44.24

News Sentiment

By Acuity

42%

58%

143 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Fresenius SE & Co KGaA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 maj 2025, 06:55 UTC

Market Talk
Earnings

Fresenius's Outlook Is Achievable -- Market Talk

26 lut 2025, 13:37 UTC

Market Talk

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

Peer Comparison

Price change

Fresenius SE & Co KGaA Forecast

Price Target

By TipRanks

11.75% upside

12 Months Forecast

Average 49.44 EUR  11.75%

High 52 EUR

Low 45 EUR

Based on 13 Wall Street analysts offering 12 month price targets forFresenius SE & Co KGaA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

42.5 / 43.2Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

143 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.